Caitlin W Hicks1, Courtenay M Holscher2, Peiqi Wang2, Chen Dun2, Christopher J Abularrage3, James H Black3, Kim J Hodgson4, Martin A Makary5. 1. Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: chicks11@jhmi.edu. 2. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3. Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Department of Vascular Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA. 5. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
OBJECTIVES: The aim of this study was to describe physician practice patterns and examine physician-level factors associated with the use of atherectomy during index revascularization for patients with femoropopliteal peripheral artery disease. BACKGROUND: There are minimal data to support the routine use of atherectomy over angioplasty and/or stenting for the endovascular treatment of peripheral artery disease. METHODS: Medicare fee-for-service claims (January 1 to December 31, 2019) were used to identify all beneficiaries undergoing elective first-time femoropopliteal peripheral vascular intervention (PVI) for claudication or chronic limb-threatening ischemia. Hierarchical logistic regression was used to evaluate patient- and physician-level characteristics associated with atherectomy. RESULTS: A total of 58,552 patients underwent index femoropopliteal PVI by 1,627 physicians. There was a wide distribution of physician practice patterns in the use of atherectomy, ranging from 0% to 100% (median 55.1%). Independent characteristics associated with atherectomy included treatment for claudication (vs. chronic limb-threatening ischemia; odds ratio [OR]: 1.51), patient diabetes (OR: 1.09), physician male sex (OR: 2.08), less time in practice (OR: 1.41 to 2.72), nonvascular surgery specialties (OR: 2.78 to 5.71), physicians with high volumes of femoropopliteal PVI (OR: 1.67 to 3.51), and physicians working primarily at ambulatory surgery centers or office-based laboratories (OR: 2.19 to 7.97) (p ≤ 0.03 for all). Overall, $266.8 million was reimbursed by Medicare for index femoropopliteal PVI in 2019. Of this, $240.6 million (90.2%) was reimbursed for atherectomy, which constituted 53.8% of cases. CONCLUSIONS: There is a wide distribution of physician practice patterns for the use of atherectomy during index PVI. There is a critical need for professional guidelines outlining the appropriate use of atherectomy in order to prevent overutilization of this technology, particularly in high-reimbursement settings.
OBJECTIVES: The aim of this study was to describe physician practice patterns and examine physician-level factors associated with the use of atherectomy during index revascularization for patients with femoropopliteal peripheral artery disease. BACKGROUND: There are minimal data to support the routine use of atherectomy over angioplasty and/or stenting for the endovascular treatment of peripheral artery disease. METHODS: Medicare fee-for-service claims (January 1 to December 31, 2019) were used to identify all beneficiaries undergoing elective first-time femoropopliteal peripheral vascular intervention (PVI) for claudication or chronic limb-threatening ischemia. Hierarchical logistic regression was used to evaluate patient- and physician-level characteristics associated with atherectomy. RESULTS: A total of 58,552 patients underwent index femoropopliteal PVI by 1,627 physicians. There was a wide distribution of physician practice patterns in the use of atherectomy, ranging from 0% to 100% (median 55.1%). Independent characteristics associated with atherectomy included treatment for claudication (vs. chronic limb-threatening ischemia; odds ratio [OR]: 1.51), patient diabetes (OR: 1.09), physician male sex (OR: 2.08), less time in practice (OR: 1.41 to 2.72), nonvascular surgery specialties (OR: 2.78 to 5.71), physicians with high volumes of femoropopliteal PVI (OR: 1.67 to 3.51), and physicians working primarily at ambulatory surgery centers or office-based laboratories (OR: 2.19 to 7.97) (p ≤ 0.03 for all). Overall, $266.8 million was reimbursed by Medicare for index femoropopliteal PVI in 2019. Of this, $240.6 million (90.2%) was reimbursed for atherectomy, which constituted 53.8% of cases. CONCLUSIONS: There is a wide distribution of physician practice patterns for the use of atherectomy during index PVI. There is a critical need for professional guidelines outlining the appropriate use of atherectomy in order to prevent overutilization of this technology, particularly in high-reimbursement settings.
Authors: John R Laird; Barry T Katzen; Dierk Scheinert; Johannes Lammer; Jeffrey Carpenter; Maurice Buchbinder; Rajesh Dave; Gary Ansel; Alexandra Lansky; Ecaterina Cristea; Tyrone J Collins; Jeffrey Goldstein; Michael R Jaff Journal: Circ Cardiovasc Interv Date: 2010-05-18 Impact factor: 6.546
Authors: James F McKinsey; Thomas Zeller; Krishna J Rocha-Singh; Michael R Jaff; Lawrence A Garcia Journal: JACC Cardiovasc Interv Date: 2014-08 Impact factor: 11.195
Authors: Caitlin W Hicks; Courtenay M Holscher; Peiqi Wang; James H Black; Christopher J Abularrage; Martin A Makary Journal: J Vasc Surg Date: 2019-06-14 Impact factor: 4.268
Authors: John G Albertini; Peiqi Wang; Christine Fahim; Susan Hutfless; Thomas Stasko; Allison T Vidimos; Barry Leshin; Elizabeth M Billingsley; Brett M Coldiron; Richard G Bennett; Victor J Marks; Angela Park; Heidi N Overton; William E Bruhn; Tim Xu; Aravind Krishnan; Martin A Makary Journal: JAMA Dermatol Date: 2019-08-01 Impact factor: 10.282
Authors: Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Thomas Zeller; Gary S Roubin; Mark W Burket; Yazan Khatib; Scott A Snyder; Anthony O Ragheb; J King White; Lindsay S Machan Journal: Circ Cardiovasc Interv Date: 2011-09-27 Impact factor: 6.546
Authors: Thomas Zeller; Ralf Langhoff; Krishna J Rocha-Singh; Michael R Jaff; Erwin Blessing; Beatrice Amann-Vesti; Marek Krzanowski; Patrick Peeters; Dierk Scheinert; Giovanni Torsello; Sebastian Sixt; Gunnar Tepe Journal: Circ Cardiovasc Interv Date: 2017-09 Impact factor: 6.546
Authors: Sarah E Deery; Earl Goldsborough; Chen Dun; Christopher J Abularrage; James H Black; Martin A Makary; Caitlin W Hicks Journal: Ann Vasc Surg Date: 2021-11-12 Impact factor: 1.466
Authors: Qingwen Kawaji; Chen Dun; Christi Walsh; Rebecca A Sorber; David P Stonko; Christopher J Abularrage; James H Black; Bruce A Perler; Martin A Makary; Caitlin W Hicks Journal: J Vasc Surg Date: 2022-03-08 Impact factor: 4.860